ライフサイエンスコーパス: daily oral administration

1 Zucker fatty rats following 1 and 2 weeks of daily oral administration.

2 olerable safety and PK is supportive of once-daily oral administration.

3 osteosarcoma xenograft model following once-daily oral administration.

4 p-AKT S129 in tumors (HCT116) following once-daily oral administration and shows a clear PK-PD relati

5 rier, and pharmacokinetics suitable for once-daily oral administration at low dose.

6 3% at 30 mg/kg in the Peters test after once daily oral administration for 4 consecutive days.

7 hieves superior antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2

8 erall technical profile compatible with once-daily oral administration in a phase 1 study, no apparen

9 Twice-daily oral administration of 10 mg/kg GS-621763 reduces

10 Daily oral administration of 20g significantly prolonged

11 Once-daily oral administration of 22 for 14 days led to 85% i

12 endent medulloblastoma allograft model after daily oral administration of 40 mg/kg of compound 28.

13 f children at high risk for type 1 diabetes, daily oral administration of 67.5 mg of insulin, compare

14 Moreover, daily oral administration of bardoxolone methyl to monke

15 KLN-205 squamous cell carcinoma mouse model, daily oral administration of EPA resulted in a significa

16 In contrast, daily oral administration of estradiol did not affect ei

17 tion by colonoscopy, followed by 12 weeks of daily oral administration of frozen encapsulated cFMT or

18 We found that daily oral administration of HF increases glucose tolera

19 We investigated the effects of daily oral administration of HFCS in adenomatous polypos

20 Once-daily oral administration of inhibitor 9i (AP24226) sign

21 Four weeks of once-daily oral administration of L-FMAU significantly reduce

22 s, mice were fed HGD or HBD with and without daily oral administration of Lp dfa1 at 1 x 10(9) CFU.

23 Conversely, daily oral administration of lysozyme prevented expansio

24 Once daily oral administration of MK-869 was effective in red

25 Daily oral administration of MRTX1719 to tumor xenograft

26 Daily oral administration of NPS 2143 to osteopenic ovar

27 In MDA-MB-231 tumor-bearing mice, daily oral administration of OSU-53 (50 and 100 mg/kg) s

28 We then determined the efficacy of daily oral administration of PD173074 for 28 days in two

29 Daily oral administration of PEA-OXA (10 mg/kg daily o.s

30 Once-daily oral administration of PVTX-405 as single agent si

31 Daily oral administration of resolvin D1, a downstream m

32 was assessed before, during and after timed daily oral administration of saline vehicle (n=12), rame

33 of abciximab and again after 1 week of twice-daily oral administration of study drug.

34 Daily oral administration of SU11657 at 40 mg/kg suppres

35 s from rats withdrawn for 2 days from 1-week daily oral administration of the benzodiazepine, fluraze

36 Daily oral administration of the peptides in WD-fed LDLr

37 Once daily oral administration of this compound at 100 mg/kg

38 drug abuse liability, animals received three daily oral administrations of these doses of MP for up t

39 n vivo model of bone turnover following once-daily oral administration, these two compounds were sele

40 We report here that daily oral administration to mice of the brain-penetrant

41 cin was administered (from 3 days prior with daily oral administration) to mice in which aortic disse

42 After 16 weeks of once- or twice-daily oral administration, treatment with the interleuki

43 C59 displayed good bioavailability, as once daily oral administration was sufficient to maintain blo

44 We demonstrate that daily oral administration with MRx0006 attenuates social

45 rts to identify a compound suitable for once daily, oral administration with low drug-drug interactio